What are research peptides?

Research peptides are short chains of amino acids — the same building blocks as proteins — synthesized in laboratory settings for use in scientific investigations. Unlike larger protein therapeutics, peptides are typically 2–50 amino acids in length, which confers unique pharmacokinetic properties including targeted receptor binding, relatively rapid degradation, and low immunogenicity. Preclinical studies explore their roles in signaling pathways across metabolic, regenerative, and neuroendocrine systems.

What is TB-500 (Thymosin Beta-4) and how does it relate to actin dynamics?

TB-500 is a synthetic version of the 43-amino acid peptide Thymosin Beta-4 (Tβ4), one of the most abundant peptides in mammalian cells. Its primary structural role is the sequestration of globular actin (G-actin), which regulates actin polymerization dynamics essential for cell migration, proliferation, and wound healing. Research has demonstrated that Tβ4 promotes the migration of keratinocytes and endothelial cells into wound sites, stimulates angiogenesis, and reduces inflammation via down-regulation of NF-κB signaling.

What is MOTS-c and how does it relate to mitochondrial signaling?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. It activates AMP-activated protein kinase (AMPK), a central energy-sensing enzyme. Research in mouse models has shown that MOTS-c administration improves insulin sensitivity, reduces high-fat-diet-induced obesity, and extends median lifespan in aged mice. Circulating MOTS-c levels decline with age in humans, making it a subject of longevity research.

What is SS-31 and what is its proposed role in mitochondrial membrane protection?

SS-31 (elamipretide) is a tetrapeptide that selectively partitions into the inner mitochondrial membrane and binds cardiolipin — a lipid essential for cristae structure and the organization of respiratory chain supercomplexes — thereby reducing electron leak, superoxide generation, and cytochrome c release. Animal models of heart failure and ischemia-reperfusion injury have demonstrated improvements in ATP production and reductions in oxidative stress with SS-31 treatment.

What is Retatrutide and what receptor systems does it target?

Retatrutide (LY3437943) is a tri-agonist peptide that activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Published phase 2 clinical trial data (NEJM, 2023) reported mean body-weight reductions of approximately 17% over 24 weeks at the highest dose studied.

What is the CJC-1295 + Ipamorelin combination and why are they studied together?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that significantly extends its plasma half-life by forming a covalent bond with albumin. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist that stimulates pituitary GH release through a separate receptor pathway. Combining GHRH analog and GHSR agonist targets both primary regulatory inputs to pituitary somatotrophs, producing synergistic GH pulses in preclinical studies while maintaining physiological pulsatility.

How are synthetic peptides stored to maintain stability?

Lyophilized (freeze-dried) peptides are the most stable form for long-term storage. In powder form, most synthetic peptides remain stable for 12–24 months when stored at −20 °C in a desiccated, light-protected environment. Reconstitution with sterile bacteriostatic water — which contains 0.9% benzyl alcohol as a preservative — allows repeated use from a single vial over several weeks when refrigerated at 2–8 °C.

BPC-157: Research Overview

Q: What is a Certificate of Analysis (COA)?

A Certificate of Analysis is a document issued by an accredited analytical laboratory confirming the identity, purity, and potency of a synthesized compound. For research peptides, a COA typically includes HPLC chromatograms, mass spectrometry data, amino acid composition analysis, and solubility data. Independent third-party COAs — generated by labs with no financial relationship to the supplier — are considered the gold standard for verifying compound quality in preclinical research.

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein found in human gastric juice. It is studied in preclinical research for its effects on tissue repair, angiogenesis, and gastrointestinal protection.

Studied mechanisms of action

Preclinical research has examined several proposed mechanisms for BPC-157. The most frequently cited is promotion of angiogenesis — the formation of new blood vessels — via upregulation of vascular endothelial growth factor (VEGF) and interaction with the nitric oxide (NO) system, which influences vasodilation and blood flow to injured tissue. Studies have also reported local upregulation of growth hormone receptors and modulation of dopaminergic and serotonergic signaling. These mechanisms are drawn largely from rodent models, particularly work from the Sikiric group at the University of Zagreb.

Tissue repair research

The largest body of BPC-157 literature concerns musculoskeletal and gastrointestinal healing in animal models. Rodent studies have reported accelerated tendon-to-bone healing, ligament and muscle repair, and protection of gastric mucosa against ulceration. A notable property reported in this research is BPC-157's apparent stability in gastric acid, which has made oral administration a subject of study in rodent gastric-lesion models — uncommon among larger peptides. Human clinical trial data remain limited, and findings should be understood as preclinical.

Anti-inflammatory pathways

Several animal studies have examined BPC-157 in the context of inflammation, reporting suppression of pro-inflammatory cytokines including TNF-α and IL-6 in models of colitis and surgically induced lesions. Proposed mechanisms include interaction with the nitric oxide system and the cyclooxygenase (COX) pathway, alongside stabilization of gastrointestinal mucosal integrity.

Purity and verification

Pokai Research BPC-157 is third-party tested by Freedom Diagnostics Testing at 99.27% purity (batch 26030284). The batch-specific Certificate of Analysis includes HPLC purity analysis and is independently verifiable using the Freedom Diagnostics search code published on the product page. Research applications require high purity so that observed biological effects can be attributed to the intended molecule rather than synthesis impurities.

Frequently asked questions

What is BPC-157 and what biological mechanisms have been studied?

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. Preclinical research has studied its effects on angiogenesis, nitric oxide signaling, and tissue repair, with rodent studies reporting accelerated tendon, muscle, and gastrointestinal healing. Human clinical data remain limited.

Source: Curr Pharm Des (2018) · PubMed

What are the proposed anti-inflammatory properties of BPC-157?

Several preclinical studies have examined BPC-157's interaction with the nitric oxide system and prostaglandin pathways as potential anti-inflammatory mechanisms. In animal models of inflammatory bowel disease, colitis, and surgically induced lesions, BPC-157 demonstrated suppression of pro-inflammatory cytokines including TNF-α and IL-6. Some research implicates modulation of the cyclooxygenase (COX) pathway and stabilization of gastrointestinal mucosal integrity. The peptide's stability in gastric acid makes oral administration theoretically feasible, a property uncommon among larger peptides, though this has primarily been studied in rodent gastric lesion models.

Source: J Physiol Pharmacol (2009) · PubMed

How is peptide purity measured and why does it matter?

Peptide purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. These techniques quantify the proportion of the target compound relative to impurities such as deletion sequences, oxidized variants, or solvent residues. Research applications require high purity — commonly ≥98% — to ensure that observed biological effects can be attributed to the intended molecule rather than contaminants. Independent third-party certificates of analysis (COAs) provide an objective record of purity at the time of synthesis.

Source: J Pept Sci (2019) · PubMed

What is a Certificate of Analysis (COA)?

A Certificate of Analysis (COA) is a document from an accredited analytical laboratory confirming a compound's identity, purity, and potency. For research peptides it typically includes HPLC chromatograms and mass spectrometry data. Independent third-party COAs are the gold standard for verifying compound quality.

Source: USP General Chapter ⟨1058⟩ · PubMed

View BPC-157 in the catalog →